University of California

The National Cyber League Announces Official Spring 2024 Cyber Power Rankings for High Schools and Colleges

Retrieved on: 
木曜日, 5月 9, 2024
University, CrowdStrike, California State University, Chico, School, NCL, Innovation, University of California, Student, SANS Institute, Colorado State University Pueblo, Face, Workforce, Arms industry

CHEVY CHASE, Md., May 9, 2024 /PRNewswire-PRWeb/ -- The National Cyber League concluded the Spring 2024 NCL Competition with participation from 8,017 students and 737 high schools, colleges, and universities from all over the United States, representing all 50 states.

Key Points: 
  • The National Cyber League concluded the Spring 2024 NCL Competition with participation from all over the United States, representing all 50 states.
  • Each season the NCL publishes its Cyber Power Rankings of the top 100 schools within the competition.
  • CHEVY CHASE, Md., May 9, 2024 /PRNewswire-PRWeb/ -- The National Cyber League concluded the Spring 2024 NCL Competition with participation from 8,017 students and 737 high schools, colleges, and universities from all over the United States, representing all 50 states.
  • The Cyber Power Rankings is a published list of the top 100 schools within the NCL, representing the hard work and skills of collegiate and high school students.

Editas Medicine Announces First Quarter 2024 Results and Business Updates

Retrieved on: 
水曜日, 5月 8, 2024
Rubius, CRISPR, Research, Paratriathlon, University of California, Intellectual property, CAFC, SCD, BMY, Editas Medicine, Gene editing, Adolescence, Medicine, Leber congenital amaurosis, Bristol Myers Squibb, Therapy, Vertex Pharmaceuticals, Cas9, Guide, Change, LSID, Emmanuelle, Blas, Public expenditure, Human, University of Vienna, Collaboration, CVC, Bluebird bio, TDT, Sale, Cancer, Cell, Quality, Senior, Patent, Patient, Liver, Gene, Society, Pharmaceutical industry

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.
  • “We made significant progress in all three pillars of our strategy this quarter, including reni-cel, in vivo, and business development, including intellectual property,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.
  • ET to provide and discuss a corporate update and financial results for the first quarter of 2024.
  • To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Retrieved on: 
木曜日, 5月 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Schizophrenia, CMO, Neuroscience, University of Toronto, University of California, Cognition, Vortioxetine, Biological Psychiatry (journal), Biomarker, Prevalence, Into, Diagnosis, Deficit spending, Drug development, Area studies, Remind, Depression, Data, Pharmacodynamics, EEG, Bipolar, Trial, Chair, Volunteering, Lab, Cognitive deficit, Doctor of Philosophy, Society, University, Cyclothymia, Randomness, ASCP, Pharmaceutical industry

“Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.

Key Points: 
  • “Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.
  • Importantly, we have systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment associated with schizophrenia in a comprehensive analysis inclusive of all major candidate biomarkers.
  • New analysis of vortioxetine Phase 3 data demonstrates that baseline cognitive performance is not a moderator of response to vortioxetine.
  • A notable relationship between theta response and processing speed, which is thought to underpin cognitive impairment in schizophrenia, was observed.

Topcon Healthcare Inc. (THI) Partners with Microsoft to Deliver AI-Powered ‘Healthcare from the Eye’ Through a Connected Healthcare Platform

Retrieved on: 
木曜日, 5月 9, 2024
Software, Research, Internet, Optical, Data Management, Technology, Artificial Intelligence, Health Technology, Security, Science, Practice Management, Health, Diabetes, Corporation, DAG, University, Safety, Policy, AI, MD, University of California, Partnership, Nuance, UC San Diego Health, Algorithm, Senior, Digital health, Microsoft, SVP, Patient, Eye, THI, Data management, Harmony, Azure, Multimedia, Distinguishing, DSM-IV codes, Organization, Optometry, UC, Management

Topcon Healthcare Inc. (THI) announces a partnership with Microsoft Corporation to deliver AI-powered ‘Healthcare from the Eye’ solutions to improve healthcare access, cost, and quality.

Key Points: 
  • Topcon Healthcare Inc. (THI) announces a partnership with Microsoft Corporation to deliver AI-powered ‘Healthcare from the Eye’ solutions to improve healthcare access, cost, and quality.
  • “We are committed to making healthcare accessible and affordable through pre-screening using oculomics - leveraging the eye for insights into systemic and neurological health.
  • We call this, ‘Healthcare from the Eye.’ A key element of this effort is Harmony - a vendor-inclusive, secure, connected data management platform,” said Ali Tafreshi, CEO & President of Topcon Healthcare Inc.
  • View the full release here: https://www.businesswire.com/news/home/20240509264153/en/
    Since establishing the Microsoft collaboration in February of 2024, THI has initiated several projects to drive the mission forward.

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
月曜日, 5月 6, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Education, FDA, CFO, Disorder, Regenerative medicine, University of California, Alexion Pharmaceuticals, PDUFA, Arena Pharmaceuticals, Danon disease, European Medicines Agency, Strategic planning, UCLA, Food, Molecule, Stanford University, Empire, BLA, Medication, Corporate communication, Definitive, Fanconi anemia, Patient, Increment, Safety, Rare disease, Regeneron Pharmaceuticals, AAV, Immunology, EMA, FA, Division, PKD, University, Marketing, MAA, Cell, Biologics license application, Pharmacology, Rare Disease Day, Disease, Mirati Therapeutics, Haematopoietic system, Gene, Society, Pyruvate kinase deficiency, Liberty Science Center, Annual general meeting, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
  • In April, Rocket announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of FA.
  • MAA acceptance was based on positive, previously disclosed data from the global RP-L102 Phase 1/2 clinical trial.
  • Mr. Ondrey was previously the CFO at Mirati Therapeutics and has held multiple senior finance leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Retrieved on: 
木曜日, 5月 2, 2024
Technology, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Artificial Intelligence, AbCellera, CFO, University, Cancer, SoftBank Vision Fund, Antimicrobial resistance, Bone marrow, HBM, Pneumonia, Head, Risk, Hospital, Metagenomics, Infection, Survival, AMR, Public, Eli Lilly, Khosla Ventures, Partnership, University of California, Research, Artificial intelligence, DNA, Partner (business rank), Transplant, Patient, Immunodeficiency, Eric Schmidt, General partnership, MD Anderson Cancer Center, Death, Growth, Pharmaceutical industry

Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.

Key Points: 
  • Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
  • The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare.
  • The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.
  • Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.

BASF and University of California, Berkeley, celebrate their successful 10-year collaboration

Retrieved on: 
火曜日, 4月 23, 2024
Stanford University, University of Southern California, University, University of California, Irvine, BASF, Research, Partnership, University of California, History, AFL–CIO, Patent, Chemistry, University of California, Berkeley, Ministry of Energy, Associate, UC, California Institute of Technology

The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.

Key Points: 
  • The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.
  • To mark the anniversary, BASF and CARA hosted a scientific symposium on sustainable transformation in chemistry on April 22.
  • Since 2014, the collaboration has expanded to 11 California universities, including UC Santa Barbara, UC Irvine as well as Stanford University, California Institute of Technology, and University of Southern California.
  • More than 80 faculty members and 170 postdocs/graduate students have worked with BASF and CARA, and BASF has hired 11 postdocs/students from the CARA community.

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

Retrieved on: 
水曜日, 5月 1, 2024
Other Health, Software, Research, Pharmaceutical, Philanthropy, Oncology, Technology, Foundation, Science, Biotechnology, Other Science, Health, FDA, University, UCSD, BTRC, Regenerative medicine, HGG, University of California, Partnership, Doctor of Philosophy, CIRM, UCSF, Patient, Analysis of variance, SOC, Enterprise, USC, Neuro

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Key Points: 
  • Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • Anova was approached to assist with the development of the product and was instrumental organizing leading neuro-scientists, developing the study plans, securing FDA approval, preparing the CIRM application, and securing the ultimate CIRM award.
  • The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed HGG when compared to historical performance.

Clinical Trial by Harvard Pilgrim Health Care Institute, HCA Healthcare, UCI Health and CDC Identifies Strategy to Rapidly Detect and Respond to Hospital Outbreaks Using Algorithm-Driven Technology

Retrieved on: 
火曜日, 4月 23, 2024
Data Management, Other Health, Technology, Managed Care, General Health, Infectious Diseases, Hospitals, Clinical Trials, Other Technology, Biotechnology, Science, Software, Networks, Other Science, Research, Health, University, Hospital, Risk, CDC, University of California, HCA Healthcare, Patient safety, Fungal infection, Doctor of Science, Patient, MPH, UCI, NEJM, Harvard Medical School, Infection, Harvard Pilgrim Health Care, Doctor of Public Health, Senior advisor, COVID-19, CLUSTER, Vaccine

The large multi-state, real-world study was conducted in 82 hospitals and led by Harvard Pilgrim Health Care Institute, HCA Healthcare, University of California, Irvine (UCI) Health and the Centers for Disease Control and Prevention (CDC).

Key Points: 
  • The large multi-state, real-world study was conducted in 82 hospitals and led by Harvard Pilgrim Health Care Institute, HCA Healthcare, University of California, Irvine (UCI) Health and the Centers for Disease Control and Prevention (CDC).
  • While hospitals and health systems work to prevent infections and reduce the opportunity for outbreaks to occur, there is no standardized approach for detecting transmission.
  • Early detection can lead to a rapid response that reduces the chance for outbreaks to occur.
  • “The CLUSTER trial provides evidence that early detection powered by automation tools and quick action can prevent outbreaks from growing."

Nancy Krystal Joins Velo3D as Vice President, General Counsel

Retrieved on: 
木曜日, 4月 11, 2024
Electronic Design Automation, Machine Tools, Metalworking & Metallurgy, Engineering, Technology, Manufacturing, Software, Hardware, Sale, Law, University, Candy, General counsel, University of California, VLD, M&A, Big Heart Pet Brands, Jelly Belly, Growth, Management

Velo3D , Inc. ( NYSE: VLD ), a leading additive manufacturing technology company for mission-critical metal parts, today announced the appointment of Nancy Krystal as Vice President, General Counsel to oversee all legal matters for the company.

Key Points: 
  • Velo3D , Inc. ( NYSE: VLD ), a leading additive manufacturing technology company for mission-critical metal parts, today announced the appointment of Nancy Krystal as Vice President, General Counsel to oversee all legal matters for the company.
  • With over 16 dynamic years of experience in corporate law, Nancy brings a wealth of experience in navigating complex legal landscapes and spearheading pivotal deals to her new role at Velo3D.
  • View the full release here: https://www.businesswire.com/news/home/20240411950967/en/
    With over 16 dynamic years in corporate law, Nancy has navigated the legal landscape with finesse, spearheading pivotal deals and ensuring compliance at every turn.
  • As General Counsel of Jelly Belly Candy Company, she orchestrated the historic sale of the company, showcasing her strategic acumen and leadership.